|
 China is looking to make testing universal, available in every
corner of the mainland.
Procurement documents and official notices show it is sharply
expanding its testing capability, already the world's largest,
extending it even to rural health facilities as it looks to revive
the economy after an unprecedented plunge in the first quarter.
On Monday, the National Health Commission said it would look to
"normalize" nucleic acid testing.
"If they're willing to be checked, check them all," said the policy
notice.
Life is increasingly returning to normal in China, where the
outbreak first emerged in the city of Wuhan late last year.
Last month, Wuhan tested around 6 million people over 10 days at a
cost of 900 million yuan ($127 million), an initiative some experts
said largely had the benefit of boosting confidence.
Unlike many countries, tests are widely available in China. Ben
Cowling, an infectious disease specialist at Hong Kong University,
said he expects many organizations in China to arrange regular
screenings of staff.
"Testing is expensive, but perhaps not as expensive in China because
the reagents and machines tend to be produced in China," he said.
"It's also not as expensive as local or city-wide lockdowns might
be, if outbreaks became larger before being identified."
NATIONWIDE BUILD-UP
Hundreds of bidding documents issued by hospitals and centers for
disease control (CDC) in every province since the beginning of May
list requirements for new testing labs, painting a picture of a
fast-paced national program.
The most expensive items are polymerase chain reaction (PCR)
machines, a key testing component documents show can cost up to
$99,000.
Chinese organizations bought 257 PCR laboratories in the last 30
days, according to listings on procurement platform Jianyu360,
compared with an average of 21 per month in the previous 12 months.
Those figures represent a fraction of the total, as not all projects
are detailed in public procurements.
[to top of second column] |
For over two weeks after the virus was identified in January, no hospitals in
Wuhan - a city of 11 million - were equipped to conduct tests, meaning no new
cases were confirmed until days before the city's lockdown.
Most of the new labs are being installed in hospitals, and most cost between
100,000 and 3 million yuan ($15,000-$420,000).
Some institutions require all equipment to be produced within China, though
others call for specific foreign-made gear, including PCRs made by Switzerland's
Roche Holding AG <ROG.S> and U.S.-based Bio-Rad Laboratories Inc <BIO.N>.
PRICE CONTROLS ON TESTS
China has said it can produce 5 million test kits a day, and provincial
governments have imposed strict price controls on manufacturers.
Hubei province, the epicenter of the outbreak, compels test makers to cut prices
for bulk orders, driving them as low as 16.78 yuan for a nucleic acid test, and
12.9 yuan for an antibody-based kit, according to figures released on May 9.
Medical institutes will be barred from offering tests if they refuse to buy kits
from the few companies that secured contracts at government-negotiated prices,
Hubei authorities said.
China does not say how many tests it has conducted, but the figure is widely
believed to far surpass other countries. By comparison, the U.S. CDC reported
over 20 million tests conducted as of June 5.
"I think everyone will take the tests, even many tests," said Lu Meiping, one of
thousands of university students set to return to Beijing this month under
quarantine and testing programs.
"No one wants to stay home."
($1 = 7.0745 Chinese yuan renminbi)
(Reporting by Cate Cadell, additional reporting by Roxanne Liu; Editing by Tony
Munroe)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
